Achievements

TBDA member organizations and their representatives have reached the following goals or acquired recognition:

The following trials have been, or are currently being run on, candidates from the TBDA portfolio

NCT Number	Compound	Phase	Start Date	Owner(Originator)	Target
NCT05382312	GSK-656	2 (EBA)	2022-07-26	GSK	LeuRS
NCT03557281	GSK-656	2 (EBA)	2019-03-22	GSK	LeuRS
NCT06114628	GSK-656	2	2024-01-09	GSK	LeuRS
NCT06354257	GSK-656	1	2024-04-05	GSK	LeuRS
NCT03075410	GSK-656	1	2017-04-02	GSK	LeuRS
NCT03199339	TBA-7371	1	2017-08-29	TB Alliance	DprE1
NCT04176250	TBA-7371	2 (EBA)	2020-01-16	Gates MRI	DprE1
NCT03758612	TBI-223	1 (SAD)	2019-01-16	TB Alliance	ribosome
NCT04865536	TBI-223	1 (MAD)	2021-02-16	TB Alliance	ribosome
NCT04890535	TBAJ-587	1 (SAD)	2020-12-01	TB Alliance	ATP synthase
NCT06058299	TBAJ-876	2 (SAD)	2020-06-08	TB Alliance	ATP synthase
NCT04493671	TBAJ-876	1 (SAD)	2020-06-08	TB Alliance	ATP synthase
NCT05526911	TBAJ-876	1	2022-06-30	TB Alliance	ATP synthase
NCT04472897	GSK-286	1 (SAD)	2020-10-30	GSK	Adenylyl cyclase
NCT05824091	MK-7762	1	2023-02-23	Gates MRI (MSD)	ribosome
NCT05388448	Sanfetrinem	2	2022-04-21	GSK	Beta-lactam
NCT06707142	(CLB073) TBD11	1 (SAD/MAD)	2024-12-05	Gates MRI (Calibr)	Adenylyl cyclase

The following TBDA member organizations have been recognized for their work:

The following TBDA member organization representatives have been recognized for their work:

Carl Nathan, MD
- Sanofi – Institut Pasteur Award (2019)
- Robert Roch Prize (2019)- “groundbreaking work which led to the elucidation of the mechanisms underlying antibacterial host defence notably against tuberculosis”
- National Academy of Sciences (2011)
Eric Rubin, MD PhD
- National Academy of Medicine (2021)
Valerie Mizrahi, Ph.D.
- Fellow of the Royal Society (2023)
- American Academy of Arts and Sciences (2025)
Kelly Chibale, Ph.D.
- National Academy of Medicine (2024)
- National Academy of Sciences (2025)

page updated 2025-06-11